

Automated Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction using Artificial Intelligence

Ashley P. Akerman PhD*^a, Mihaela Porumb PhD*^a, Christopher G. Scott MS^b, Arian Beqiri PhD^a, Agisilaos Chartsias PhD^a, Alexander J. Ryu MD^c, William Hawkes PhD^a, Geoffrey D. Huntley MD^d, Ayana Z. Arystan MD^d, Garvan C. Kane MD^d, Sorin V. Pislaru MD^d, Francisco Lopez-Jimenez MD^d, Alberto Gomez PhD^a, Rizwan Sarwar MRCP^{a,e,f}, Jamie O'Driscoll PhD^{a,g}, Paul Leeson MB^{a,e}, Ross Upton PhD^a, Gary Woodward PhD^a, Patricia A. Pellikka MD^d

^a Ultrasonics Ltd, 4630 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, OX4 2SU, UK, ^b Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA, ^c Division of Hospital Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, USA, ^d Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, USA, ^e Cardiovascular Clinical Research Facility, University of Oxford, Oxford, OX3 7JX, UK, ^f Experimental Therapeutics, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK, ^g Department of Cardiology, St George's University Hospitals NHS Foundation Trust, London, UK, * denotes joint first authorship

INTRODUCTION

Detection of heart failure with preserved ejection fraction (HFpEF) involves integration of multiple imaging and clinical features which are often discordant or indeterminate.


We hypothesized that applying artificial intelligence (AI) to the apical 4 chamber (A4C) echo videoclip, which contains a vast amount of information, might allow detection of HFpEF.

AIM

To develop an AI model to detect HFpEF from analysis of a single A4C transthoracic echocardiogram videoclip.

METHODS




A three-dimensional convolutional neural network was developed and trained on A4C videoclips to classify patients with HFpEF (diagnosis of HF, EF≥50%, and echocardiographic evidence of increased filling pressure; cases) versus without HFpEF (EF≥50%, no diagnosis of HF, normal filling pressure; controls).



Model outputs were classified as HFpEF, no HFpEF, or non-diagnostic (high uncertainty). Performance was assessed in an independent multi-site dataset and compared to the previously validated clinical scores, HFA-PEFF and H2FPEF. For the test group, mortality was evaluated using the Kaplan-Meier method, censoring subjects at last follow-up. Survival curves and Cox proportional hazards regression estimate of hazard ratio were adjusted for age.

RESULTS

Training and validation included 2971 cases and 3785 controls (validation holdout, 16.8% patients), and demonstrated excellent discrimination (AUROC:0.97 [95%CI:0.96-0.97] and 0.95 [0.93-0.96] in training and validation, respectively). In independent testing (646 cases, 638 controls), 94 (7.3%) were non-diagnostic; sensitivity (87.8%; 84.5-90.9%) and specificity (81.9%; 78.2-85.6%) were maintained in clinically relevant subgroups, with high repeatability and reproducibility. Of 701 and 776 indeterminate outputs from the HFA-PEFF and H2FPEF scores, the AI HFpEF model correctly reclassified 73.5 and 73.6%, respectively. During follow-up (median [IQR]:2.3 [0.5-5.6] years), 444 (34.6%) patients in the test group died; mortality was higher in patients classified as HFpEF by AI (hazard ratio [95%CI]:1.9 [1.5-2.4]).



LIMITATIONS

It is possible that some controls had subclinical disease. Complete matching for age was not possible; patients with HFpEF for older. However, survival analysis was age-adjusted and sensitivity analysis demonstrated no meaningful change in interpretation in a subgroup of age-matched patients.

CONCLUSIONS

This novel AI HFpEF model based on a single, routinely acquired echocardiographic video demonstrated excellent discrimination of patients with versus without HFpEF, more often than clinical scores, and identified patients with higher mortality.

The application of this classifier in the screening for HFpEF, particularly when their diagnosis is uncertain, has the potential to automate an accurate detection process for a complex clinical syndrome, resulting in more patients getting a correct and expeditious diagnosis.

FUTURE WORK

The model must be recalibrated in other patient groups, its application validated in other echo laboratories and in different demographic groups, and its comparative effectiveness with clinical scores prospectively assessed.

REFERENCES

Akerman AP, Porumb M, Scott CG, et al. Automated Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction using Artificial Intelligence (in press) JACC Advances

ACKNOWLEDGEMENTS

This work was supported by grants from the American Society of Echocardiography Foundation and Ultrasonics Ltd. Dr. Pellikka is supported as the Betty Knight Scripps Professor of Cardiovascular Disease Clinical Research, Mayo Clinic.